CL-SBP-101-04
07 Dec 2020
Trial Summary
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
Acronym:
CL-SBP-101-04
ACTRN/NCT /ethics:
NCT05254171
Scientific title:
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Sponsor / Cooperative group:
Panbela Therapeutics, Inc.
Trial & Patient Characteristics
| Cancer Type | Pancreas |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II & Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2022-08-08 |
| Anticipated End Date | 2024-05-31 |
Participating Hospitals
| Hospital | Icon Cancer Centre - Tennyson and Windsor Garden |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| Sue.Yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Carolyn Bampton |
| Recruitment Status | Recruiting |